TABLE 2.
Baseline characteristics of included patients.
| Characteristic | COU-AA-301 | Sun et al. (2016) | AFFIRM | TROPIC | ALSYMPCA a | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Abi | Placebo | Abi | Placebo | Enza | Placebo | Caba | Placebo | Ra-223 | Placebo | |
| Median age (years) | 69 | 69 | Mean: 68.2 | Mean: 67.7 | 69 | 69 | 68 | 67 | 71 | 71 |
| Median PSA (ng/ml) | 128.8 | 137.7 | Mean: 800.0 | Mean: 527.8 | 107.7 | 128.3 | 143.9 | 127.5 | 146 | 173 |
| Gleason score<8 | 49% | 46% | 36% | 28% | 50% | 48% | NA | NA | NA | NA |
| Gleason score ≥8 | 51% | 54% | 64% | 72% | 50% | 52% | NA | NA | NA | NA |
| Bone metastasis | 89% | 90% | 95% | 94% | 92% | 92% | 80% | 87% | 100% | 100% |
| Lung metastasis | 13% | 11% | 8% | 13% | 15% | 15% | Visceral: 25% | Visceral: 25% | 0% | 0% |
| Liver metastasis | 11% | 8% | 4% | 3% | 12% | 9% | 0% | 0% | ||
| ECOG score<2 | 90% | 89% | 92% | 93% | 91% | 92% | 93% | 91% | 87% | 87% |
| ECOG score≥2 | 10% | 11% | 8% | 7% | 9% | 8% | 7% | 9% | 13% | 13% |
Abbreviations: Abi, abiraterone; Caba, cabazitaxel; Enza: enzalutamide; NA, not available; Ra-223, radium-223.
a
Data of overall population.